Market Indices
Sector Heatmap
PLSE — Pulse Biosciences, Inc Common Stock (DE)
NasdaqPulse Biosciences, Inc Common Stock (DE)
- O
- 49.11
- H
- 49.93
- L
- 48.13
- V
- 409.37K
PLSE — Latest News & Headlines
18 StoriesPulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data - Yahoo Finance
Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data Yahoo Finance
A heart-rhythm trial reached its goal three months early, enrolling 164 evaluable patients. - Stock Titan
A heart-rhythm trial reached its goal three months early, enrolling 164 evaluable patients. Stock Titan
Pulse Biosciences (NasdaqCM:PLSE) Stock Price - Simply Wall Street
Pulse Biosciences (NasdaqCM:PLSE) Stock Price Simply Wall Street
Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE) - Seeking Alpha
Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE) Seeking Alpha
Canaccord raises Pulse Biosciences stock price target on tech potential - Investing.com
Canaccord raises Pulse Biosciences stock price target on tech potential Investing.com
(PLSE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
(PLSE) Movement Within Algorithmic Entry Frameworks Stock Traders Daily
PLSE Maintained by Canaccord Genuity -- Price Target Raised to $58 - GuruFocus
PLSE Maintained by Canaccord Genuity -- Price Target Raised to $58 GuruFocus
Pulse Biosciences stock reaches 164 patient study target - AD HOC NEWS
Pulse Biosciences stock reaches 164 patient study target AD HOC NEWS
Pulse Biosciences Stock After Trial Enrollment Completion and Upcoming Data Presentation - Simply Wall Street
Pulse Biosciences Stock After Trial Enrollment Completion and Upcoming Data Presentation Simply Wall Street
PLSE Oct 2026 36.000 put (PLSE261016P00036000) Interactive Stock Chart - Yahoo! Finance Canada
PLSE Oct 2026 36.000 put (PLSE261016P00036000) Interactive Stock Chart Yahoo! Finance Canada
Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall - AD HOC NEWS
Pulse Biosciences stock faces Oppenheimer meeting after 3.87 percent fall AD HOC NEWS
How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story - Simply Wall Street
How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story Simply Wall Street
VISN,STAA,WEST,RXO,SLND,PLSE,UEIC,VANI,GRNT,ABR,TPL,CAUD,RMCF,GUG,QRHC,VRME,CRGY | Stock Prices | Quote Comparison - Yahoo! Finance Canada
VISN,STAA,WEST,RXO,SLND,PLSE,UEIC,VANI,GRNT,ABR,TPL,CAUD,RMCF,GUG,QRHC,VRME,CRGY | Stock Prices | Quote Comparison Yahoo! Finance Canada
Canaccord raises target for Pulse Biosciences stock from USD 43.00 to USD 58.00 - AD HOC NEWS
Canaccord raises target for Pulse Biosciences stock from USD 43.00 to USD 58.00 AD HOC NEWS
BTIG sets a USD 70 target for Pulse Biosciences stock - AD HOC NEWS
BTIG sets a USD 70 target for Pulse Biosciences stock AD HOC NEWS
PLSE: Clinical Progress Supports The Case, Pivotal Proof And Partnerships Still Decide - Simply Wall Street
PLSE: Clinical Progress Supports The Case, Pivotal Proof And Partnerships Still Decide Simply Wall Street
Pulse Biosciences stock gets a higher fair value estimate - AD HOC NEWS
Pulse Biosciences stock gets a higher fair value estimate AD HOC NEWS
Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial - TipRanks
Pulse Biosciences Completes Enrollment in NANOPULSE-AF Trial TipRanks